Advancing Global Care with Emerging BTKi in Relapsed/Refractory CLL: Connecting Hematology Leaders to Worldwide Learners

Published: March 30, 2023, 4 a.m.

Host: Anthony Mato, MD, MSCE
\n\n Guest: Toby A. Eyre, MD, MBChB
\n\n Guest: Talha Munir, PhD
\n\n\n \n

The validation of targeted agent classes, driven by the emergence of BTK inhibitors as a highly effective therapeutic tool, has transformed the medical management of CLL/SLL and led to similar advances for other B-cell malignancies. Although this transformation has substantially improved outcomes, challenges remain and are centered on the problem of devising truly individualized sequential care in the relapsed/refractory disease setting, where outcomes to date have not improved as dramatically as those for newly diagnosed/treatment-na\xefve disease. Therapeutic intolerance and challenges involving adverse event management, BTK inhibitor resistance, and double-refractory status contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options.

The educational activity, featuring an expert panel discussion comprised of 1 US and 2 international faculty thought leaders, will provide an evaluation of the most recent clinical data and expert insights on the current and emerging evidence supporting the clinical utility of BTK inhibitors in relapsed/refractory CLL/SLL.